Pfizer Return on Tangible Equity 1986-2025 | PFE

Current and historical return on tangible equity values for Pfizer (PFE) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Pfizer Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2025-06-30 $10.75B $-32.69B -31.64%
2025-03-31 $7.88B $-31.78B -21.76%
2024-12-31 $8.03B $-35.44B -21.03%
2024-09-30 $4.25B $-36.00B -10.59%
2024-06-30 $-2.60B $-41.71B 8.71%
2024-03-31 $-0.31B $-39.57B 1.74%
2023-12-31 $2.12B $-43.40B -35.51%
2023-09-30 $10.48B $5.45B 202.57%
2023-06-30 $21.47B $6.32B 281.19%
2023-03-31 $29.05B $7.76B 354.91%
2022-12-31 $31.37B $1.17B 453.96%
2022-09-30 $29.77B $15.30B 402.58%
2022-06-30 $29.31B $8.51B 811.15%
2022-03-31 $24.97B $2.66B -10680.64%
2021-12-31 $21.98B $3.11B -703.67%
2021-09-30 $19.43B $0.17B -258.89%
2021-06-30 $12.76B $-6.88B -91.88%
2021-03-31 $10.68B $-8.90B -56.16%
2020-12-31 $9.16B $-14.42B -38.64%
2020-09-30 $7.73B $-25.33B -31.20%
2020-06-30 $13.94B $-27.43B -52.60%
2020-03-31 $15.50B $-27.63B -59.02%
2019-12-31 $16.03B $-18.69B -60.60%
2019-09-30 $16.22B $-32.27B -57.94%
2019-06-30 $12.65B $-26.45B -46.45%
2019-03-31 $11.48B $-28.37B -39.99%
2018-12-31 $11.15B $-24.86B -37.19%
2018-09-30 $23.82B $-29.26B -74.36%
2018-06-30 $22.55B $-32.30B -62.82%
2018-03-31 $21.75B $-33.54B -54.73%
2017-12-31 $21.31B $-33.04B -49.06%
2017-09-30 $9.81B $-44.69B -20.88%
2017-06-30 $8.32B $-47.67B -17.51%
2017-03-31 $7.30B $-48.34B -16.86%
2016-12-31 $7.22B $-47.26B -19.29%
2016-09-30 $6.27B $-46.92B -19.91%
2016-06-30 $7.04B $-30.59B -27.51%
2016-03-31 $7.62B $-24.81B -38.29%
2015-12-31 $6.96B $-23.60B -43.91%
2015-09-30 $8.36B $-23.39B -73.63%
2015-06-30 $8.90B $-7.82B -155.92%
2015-03-31 $9.18B $-8.60B -203.23%
2014-12-31 $9.14B $-5.61B -304.70%
2014-09-30 $10.48B $-0.79B -359.26%
2014-06-30 $10.40B $-3.07B -268.97%
2014-03-31 $21.58B $-2.52B -489.67%
2013-12-31 $22.00B $-5.28B -436.94%
2013-09-30 $25.75B $-4.60B -468.44%
2013-06-30 $26.37B $-5.23B -392.72%
2013-03-31 $15.53B $-5.03B -179.32%
2012-12-31 $14.57B $-7.13B -132.53%
2012-09-30 $9.69B $-9.46B -77.59%
2012-06-30 $10.22B $-13.01B -80.20%
2012-03-31 $9.58B $-14.38B -74.87%
2011-12-31 $10.01B $-13.13B -80.67%
2011-09-30 $11.46B $-10.48B -92.21%
2011-06-30 $8.59B $-13.20B -64.11%
2011-03-31 $8.45B $-12.82B -57.43%
2010-12-31 $8.26B $-13.22B -52.34%
2010-09-30 $6.13B $-14.35B -35.14%
2010-06-30 $8.15B $-18.50B -119.98%
2010-03-31 $7.93B $-17.05B 196.24%
2009-12-31 $8.64B $-19.95B 62.52%
2009-09-30 $8.13B $28.33B 34.71%
2009-06-30 $7.53B $24.83B 32.61%
2009-03-31 $8.05B $22.04B 34.77%
2008-12-31 $8.10B $18.56B 33.59%
2008-09-30 $10.56B $27.00B 41.79%
2008-06-30 $9.05B $24.99B 36.74%
2008-03-31 $7.54B $25.97B 30.85%
2007-12-31 $8.14B $23.13B 32.64%
2007-09-30 $14.87B $24.40B 57.85%
2007-06-30 $17.47B $24.21B 68.68%
2007-03-31 $18.62B $28.08B 75.34%
2006-12-31 $19.34B $26.13B 87.34%
2006-09-30 $12.62B $23.34B 62.35%
2006-06-30 $10.85B $21.30B 60.55%
2006-03-31 $11.90B $17.80B 76.40%
2005-12-31 $8.09B $18.54B 56.40%
2005-09-30 $8.18B $14.03B 65.33%
2005-06-30 $9.93B $11.92B 83.18%
2005-03-31 $9.33B $12.86B 82.48%
2004-12-31 $11.36B $11.27B 108.23%
2004-09-30 $9.14B $11.71B 95.57%
2004-06-30 $8.03B $9.42B 84.72%
2004-03-31 $1.58B $9.59B 16.07%
2003-12-31 $3.91B $7.52B 29.37%
2003-09-30 $6.17B $11.38B 38.79%
2003-06-30 $6.28B $10.75B 35.97%
2003-03-31 $11.83B $23.61B 61.74%
2002-12-31 $9.13B $17.83B 51.51%
2002-09-30 $8.23B $17.65B 47.25%
2002-06-30 $7.95B $17.54B 46.00%
2002-03-31 $7.82B $17.85B 46.26%
2001-12-31 $7.79B $16.60B 47.40%
2001-09-30 $7.25B $17.13B 45.74%
2001-06-30 $6.54B $16.04B 43.11%
2001-03-31 $5.86B $15.95B 40.55%
2000-12-31 $3.73B $14.29B 29.06%
2000-09-30 $3.26B $14.41B 28.90%
2000-06-30 $3.30B $13.17B 34.05%
2000-03-31 $2.86B $9.44B 34.16%
1999-12-31 $3.88B $8.12B 48.04%
1999-09-30 $3.63B $8.01B 45.21%
1999-06-30 $3.63B $7.87B 45.56%
1999-03-31 $3.55B $8.26B 45.38%
1998-12-31 $3.43B $8.00B 45.77%
1998-09-30 $3.28B $7.76B 45.80%
1998-06-30 $2.47B $7.28B 36.75%
1998-03-31 $2.30B $6.92B 36.16%
1997-12-31 $2.21B $6.64B 36.38%
1997-09-30 $2.16B $6.09B 37.18%
1997-06-30 $2.08B $5.83B 37.38%
1997-03-31 $2.01B $5.78B 38.54%
1996-12-31 $1.93B $5.53B 39.19%
1996-09-30 $1.84B $5.09B 39.87%
1996-06-30 $1.75B $4.51B 40.07%
1996-03-31 $1.67B $4.56B 40.36%
1995-12-31 $1.57B $4.26B 40.65%
1995-09-30 $1.50B $4.11B 39.34%
1995-06-30 $1.41B $3.61B 37.63%
1995-03-31 $1.35B $3.49B 36.33%
1994-12-31 $1.30B $4.00B 34.71%
1994-09-30 $1.25B $3.86B 34.34%
1994-06-30 $0.70B $3.50B 19.56%
1994-03-31 $0.70B $3.61B 18.97%
1993-12-31 $0.66B $3.63B 17.23%
1993-09-30 $0.65B $3.63B 16.21%
1993-06-30 $1.16B $3.88B 26.51%
1993-03-31 $1.13B $4.13B 24.55%
1992-12-31 $1.08B $4.35B 22.71%
1992-09-30 $0.80B $5.14B 16.56%
1992-06-30 $0.78B $4.72B 16.53%
1992-03-31 $0.73B $4.73B 15.95%
1991-12-31 $0.72B $4.68B 15.71%
1991-09-30 $0.88B $4.62B 19.14%
1991-06-30 $0.84B $4.38B 18.50%
1991-03-31 $0.82B $4.71B 18.03%
1990-12-31 $0.80B $4.59B 18.11%
1990-09-30 $0.73B $4.57B 17.04%
1990-06-30 $0.71B $4.24B 16.90%
1990-03-31 $0.69B $4.30B 16.88%
1989-12-31 $0.68B $4.11B 16.82%
1989-09-30 $0.74B $4.12B 15.54%
1989-06-30 $0.74B $3.90B 15.74%
1989-03-31 $0.81B $4.09B 17.41%
1988-12-31 $0.79B $6.86B 17.21%
1988-09-30 $0.79B $3.85B 20.70%
1988-06-30 $0.76B $3.88B 20.28%
1988-03-31 $0.72B $3.82B 19.92%
1987-12-31 $0.69B $3.67B 19.75%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $201.199B $100.330B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12